Translations:Anti-obesity medication/21/en: Difference between revisions

From Azupedia
Jump to navigation Jump to search
VisualWikitext
FuzzyBot (talk | contribs)
15,162 edits
Importing a new version from external source
Tags: Mobile edit Mobile web edit
 
(No difference)

Latest revision as of 18:16, 7 March 2024

Information about message (contribute)
This message has no documentation. If you know where or how this message is used, you can help other translators by adding documentation to this message.
Message definition (Anti-obesity medication)
{| class="wikitable"
|+
!Medication Name
!Trade name(s)
!Mechanism of action
!Current FDA Status
!placebo-adjusted percent bodyweight lost (highest dose studied)
|-
|[[Retatrutide]]
|
|GLP-1, [[GIP receptor|GIP]], and [[glucagon receptor]] triple agonist
|In clinical trials
|24 percent in a Phase II trial
|-
|[[Exenatide]]
|Byetta
|[[GLP-1 receptor agonist]]
|Approved for type 2 diabetes
|{{convert|2.5|kg}}
|-
|[[Cetilistat]]
|
|Absorption inhibitor
|Not approved
| {{convert|1.5|kg}}
|-
| [[Tesofensine]] (NS2330)
|
|[[Serotonin–norepinephrine–dopamine reuptake inhibitor]]
|Not FDA approved
|10.6 percent
Medication Name Trade name(s) Mechanism of action Current FDA Status placebo-adjusted percent bodyweight lost (highest dose studied)
Retatrutide GLP-1, GIP, and glucagon receptor triple agonist In clinical trials 24 percent in a Phase II trial
Exenatide Byetta GLP-1 receptor agonist Approved for type 2 diabetes 2.5 kilograms (5.5 lb)
Cetilistat Absorption inhibitor Not approved 1.5 kilograms (3.3 lb)
Tesofensine (NS2330) Serotonin–norepinephrine–dopamine reuptake inhibitor Not FDA approved 10.6 percent
Retrieved from "https://wiki.tiffa.net/w/index.php?title=Translations:Anti-obesity_medication/21/en&oldid=125277"